申请人:Freyne Eddy Jean Edgard
公开号:US20100160310A1
公开(公告)日:2010-06-24
The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z
1
and Z
2
represent NH; Y represents —C
3-9
alkyl-, —C
3-9
alkenyl-, —C
1-5
alkyl-NR
6
—C
1-5
alkyl-, —C
1-5
alkyl-NR
7
—CO—C
1-5
alkyl-, —C
1-6
alkyl-CO—NH—, —C
1-6
alkyl-NH—CO—, —C
1-2
alkyl-CO-Het
10
-CO—, —C
1-3
alkyl-NH—CO-Het
3
-, -Het
4
-C
1-3
alkyl-CO—NH—C
1-3
alkyl-, —C
1-2
alkyl-NH—CO-L
1
-NH—, —NH—CO-L
2
-NH—, —C
1-2
alkyl-CO—NH-L
3
-CO—, —C
1-2
alkyl-NH—CO-L
1
-NH—CO—C
1-3
alkyl-, —C
1-2
alkyl-CO—NH-L
3
-CO—NH—C
1-3
alkyl-, —C
1-2
alkyl-NR
11
—CH
2
—CO—NH—C
1-3
alkyl-, Het
5
-CO—C
1-2
alkyl-, (C
1-5
alkyl-CO—NH—C
1-3
alkyl-CO—NH, —C
1-5
alkyl-NR
13
—CO—C
1-3
alkyl-NH—, —C
1-3
alkyl-NH—CO-Het
27
-CO—, or —C
1-3
alkyl-CO-Het
28
-CO—NH—; X
1
represents a direct bond, O, —O—C
1-2
alkyl-, —CO—C
1-2
alkyl-, —NR
16
—C
1-2
alkyl-, —CO—NR
17
—, Het
23
-C
1-2
alkyl- or C
1-2
alkyl; X
2
represents a direct bond, O, —O—C
1-2
alkyl-, —CO—C
1-2
alkyl-, —NR
18
—C
1-2
alkyl-, —CO—NR
19
—, Het
24
—C
1-2
alkyl- or C
1-2
alkyl; R
1
and R
5
each independently represent hydrogen, halo, C
1-6
alkyloxy- or C
1-6
alkyloxy- substituted with Het
1
or C
1-4
alkyloxy-; R
2
and R
4
each independently represent hydrogen or halo; R
3
represents hydrogen or cyano; R
6
, R
7
, R
13
, R
17
and R
19
represent hydrogen; R
11
represents hydrogen or C
1-4
alkyl; R
16
and R
18
represent hydrogen, C
1-4
alkyl or Het
17
-C
1-4
alkyl-; L
1
, L
2
and L
3
each independently represents C
1-8
alkyl optionally substituted with one or where possible two or more substituents selected from phenyl, methylsulfide, cyano, polyhaloC
1-4
alkyl-phenyl-, C
1-4
alkyloxy, pyridinyl, mono- or di(C
1-4
alkyl)-amino- or C
3-6
cycloalkyl; Het
1
, Het
2
, Het
17
each independently represent morpholinyl, oxazolyl, isoxazolyl, or piperazinyl; Het
3
, Het
4
, Het
5
each independently represent morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl; Het
10
represents piperazinyl, piperidinyl, pyrrolidinyl or azetidinyl; Het
22
represents morpholinyl, oxazolyl, isoxazolyl or piperazinyl wherein said Het
22
is optionally substituted with C
1-4
alkyl; Het
23
and Het
24
each independently represent a heterocycle selected from pyrrolidinyl, piperazinyl or piperidinyl wherein said Het
23
or Het
24
are optionally substituted with Het
22
-carbonyl; Het
27
and Het
28
each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl.